Stockreport

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Centessa Pharmaceuticals plc - American Depositary Shares  (CNTA) 
PDF Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexi [Read more]